Prostate Tumor Microenvironment Alters Immune Cells and Prevents Long-Term Survival in an Orthotopic Mouse Model Following flt3-Ligand/CD40-Ligand Immunotherapy-Reference-Cited by-同舟云学术

Prostate Tumor Microenvironment Alters Immune Cells and Prevents Long-Term Survival in an Orthotopic Mouse Model Following flt3-Ligand/CD40-Ligand Immunotherapy

Published:2004-01 Issue:1 Volume:27 Page:13-26
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:Journal of Immunotherapy

Author:

Ciavarra Richard P.,Holterman Daniel A.,Brown Roy R.,Mangiotti Patricia,Yousefieh Nazita,Wright, George L.,Schellhammer Paul F.,Glass W. F.,Somers Kenneth D.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference48 articles.

1. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12

2. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

3. Biologic and immunologic approaches to comprehensive therapy for pediatric malignant conditions. Laboratory–clinical interaction

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis and management of neuroendocrine prostate cancer;The Prostate;2024-01-03

2. Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer;American Society of Clinical Oncology Educational Book;2021-06

3. Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options;Urologic Clinics of North America;2020-11

4. Strategies to Target Tumor Immunosuppression;Cancer Immunology;2020-09-25

5. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study;Journal of Clinical Oncology;2020-02-10